

ASTRIA CONNECTION

Issue #3 | May 2022



Raising Awareness, Step By Step

May 16th will mark the 11th anniversary of HAEDay:-)
a global event designed to raise awareness about hereditary angioedema (HAE).

The event is organized by HAE International (HAEi), a global non-profit network of 93 patient associations dedicated to improving the lives of people with HAE. The goal of HAEDay is to raise awareness for HAE among healthcare professionals, industry, and the greater public.



Stepping Up for the Global HAE Movement

In support of this goal, HAEi has launched an activity challenge called “Stepping Up for the Global HAE Movement.” In this activity, participants log their physical and wellbeing activities in order to beat the existing record for how many times the community can walk around the world. The Astria team has been walking, running, swimming, biking, and more since the challenge opened on April 1st. Learn more about how to participate at HAEDay.org.

Meet Sarah

We are excited to introduce you to Sarah Friedhoff, our Director of Patient Advocacy! Sarah's goal is to ensure the preferences, interests, and insights of those living with HAE inform and drive all that we do: from the development of our products, to the design of our clinical trials, and more.

"Engaging with the HAE community at every step of development is critical and it enables us to try to meet our goal of raising the bar for HAE treatments. I am excited to have joined such a passionate team at Astria and am grateful to be a steward for the ideas, insights, and feedback of the HAE community."



To connect with Sarah, email:
advocacy@astriatx.com

About STAR-0215

We are charting a new path for people living with HAE -- one that envisions an opportunity for a better quality of life with a safe and effective long-acting preventative therapy with dosing once every 3 months or longer.

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein that is currently in preclinical development for the treatment of HAE. We expect to file an Investigational New Drug application for **STAR-0215** mid-year, and plan to initiate a Phase 1a clinical trial shortly thereafter, with initial results anticipated by year-end. We plan to initiate a Phase 1b/2 trial in people living with HAE in 2023.

Stay in touch!

Sign up to join our community and receive our newsletters in your inbox: <https://astriatx.com/index.html#for-patients>

For advocacy questions: advocacy@astriatx.com
Follow us on social media: [@AstriaTx](#)

